Literature DB >> 33982196

Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients.

Srilakshmi Vallabhaneni1, Kathleen W Zhang2, Jose A Alvarez-Cardona2, Joshua D Mitchell2, Henning Steen3, Pamela K Woodard4, Daniel J Lenihan2.   

Abstract

The purpose of this review is to provide an overview of the essential role that cardiovascular magnetic resonance (CMR) has in the field of cardio-oncology. Recent findings: CMR has been increasingly used for early identification of cancer therapy related cardiac dysfunction (CTRCD) due to its precision in detecting subtle changes in cardiac function and for myocardial tissue characterization. Summary: CMR is able to identify subclinical CTRCD in patients receiving potentially cardiotoxic chemotherapy and guide initiation of cardio protective therapy. Multiparametric analysis with myocardial strain, tissue characterization play a critical role in understanding important clinical questions in cardio-oncology.

Entities:  

Keywords:  CMR; Cancer therapy related cardiac dysfunction (CTRCD); Cardio-oncology; Imaging

Year:  2021        PMID： 33982196     DOI： 10.1007/s10554-021-02271-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN： 1569-5794            Impact factor:   2.357


  87 in total

1.  Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?

Authors:  N G Bellenger; M I Burgess; S G Ray; A Lahiri; A J Coats; J G Cleland; D J Pennell
Journal:  Eur Heart J       Date:  2000-08       Impact factor: 29.983

2.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Juan Carlos Plana; Maurizio Galderisi; Ana Barac; Michael S Ewer; Bonnie Ky; Marielle Scherrer-Crosbie; Javier Ganame; Igal A Sebag; Deborah A Agler; Luigi P Badano; Jose Banchs; Daniela Cardinale; Joseph Carver; Manuel Cerqueira; Jeanne M DeCara; Thor Edvardsen; Scott D Flamm; Thomas Force; Brian P Griffin; Guy Jerusalem; Jennifer E Liu; Andreia Magalhães; Thomas Marwick; Liza Y Sanchez; Rosa Sicari; Hector R Villarraga; Patrizio Lancellotti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10       Impact factor: 6.875

3.  Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.

Authors:  Mariana L Henry; Jiangong Niu; Ning Zhang; Sharon H Giordano; Mariana Chavez-MacGregor
Journal:  JACC Cardiovasc Imaging       Date:  2018-08

Review 4.  Incidental extracardiac findings on cardiac MR: Systematic review and meta-analysis.

Authors:  Vincent Dunet; Juerg Schwitter; Reto Meuli; Catherine Beigelman-Aubry
Journal:  J Magn Reson Imaging       Date:  2015-09-23       Impact factor: 4.813

5.  Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment.

Authors:  Eleanor E R Harris; Candace Correa; Wei-Ting Hwang; Jessica Liao; Harold I Litt; Victor A Ferrari; Lawrence J Solin
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

Review 6.  Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level.

Authors:  Ana Barac; Gillian Murtagh; Joseph R Carver; Ming Hui Chen; Andrew M Freeman; Joerg Herrmann; Cezar Iliescu; Bonnie Ky; Erica L Mayer; Tochi M Okwuosa; Juan Carlos Plana; Thomas D Ryan; Anne K Rzeszut; Pamela S Douglas
Journal:  J Am Coll Cardiol       Date:  2015-06-30       Impact factor: 24.094

7.  Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy.

Authors:  Frank Grothues; Gillian C Smith; James C C Moon; Nicholas G Bellenger; Peter Collins; Helmut U Klein; Dudley J Pennell
Journal:  Am J Cardiol       Date:  2002-07-01       Impact factor: 2.778

8.  Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.

Authors:  R G Schwartz; W B McKenzie; J Alexander; P Sager; A D'Souza; A Manatunga; P E Schwartz; H J Berger; J Setaro; L Surkin
Journal:  Am J Med       Date:  1987-06       Impact factor: 4.965

9.  Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood.

Authors:  Els Vandecruys; Veerle Mondelaers; Daniel De Wolf; Yves Benoit; Bert Suys
Journal:  J Cancer Surviv       Date:  2011-06-01       Impact factor: 4.442

10.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter
Journal:  Eur Heart J       Date:  2016-08-26       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.